A Study on the Efficacy of Disitamab Vedotin in Advanced HER2-positive Paget's Disease.

Summary

This study is a single-center, phase II clinical trial. Patients with HER2-positive advanced breast and extramammary Paget's disease who met the eligibility criteria were enrolled after signing an informed consent form. All patients received treatment with 2mg/kg of trastuzumab deruxtecan intravenous infusion every 3 weeks until disease progression. Follow-up was conducted until disease progression, withdrawal of informed consent by the subject, loss to follow-up, or death. Clinical tumor imaging assessments were performed using RECIST during the treatment process.

Timeline

Start

2024-08-15

Primary completion

2025-08-15

Completion

2027-08-15

Drugs

Indications